Class: beta-Adrenergic Blocking Agents
VA Class: CV100
Chemical Name: (±)-N-[3-Acetyl-4-[2-hydroxy-3-[(1-meth ylethyl)amino]propoxy]phenyl]butanamide monohydrochloride
Molecular Formula: C18H28N2O4• HCl
CAS Number: 34381-68-5
A short-acting β1-selective adrenergic blocking agent (β-blocker).1 2 17 18 113
Uses for Acebutolol Hydrochloride
Management of hypertension (alone or in combination with other classes of antihypertensive agents).1 280 500
β-Adrenergic blocking agents (β-blockers) generally not preferred for initial management of hypertension, but may be considered in patients who have a compelling indication (e.g., prior MI, ischemic heart disease, heart failure) for their use or as add-on therapy in those who do not respond adequately to the preferred drug classes (ACE inhibitors, angiotensin II receptor antagonists, calcium-channel blockers, or thiazide diuretics).361 501 502 503 504 515 523 524 527 800
Black hypertensive patients generally tend to respond better to monotherapy with calcium-channel blockers or thiazide diuretics than to β-blockers.355 359 360 500 501 504 However, diminished response to β-blockers is largely eliminated when administered concomitantly with a thiazide diuretic.500
Treatment of frequent ventricular premature complexes (VPCs), including uniform and multiform VPCs and/or coupled VPCs, and R-on-T complexes1 2 137 185 186 187 188 189 190 193 194 195 196 197 198 199 201 204 in patients with primary arrhythmias or arrhythmias secondary to various cardiac disorders (e.g., CAD,137 185 186 187 188 189 194 acute MI,137 186 187 193 194 195 196 valvular disease).185 186 187 189 190
Management of various supraventricular tachyarrhythmias†.191 192 196 200 202 203 256 266
Management of chronic stable angina pectoris†.205 206 207 208 209 210 211 212 213 214 220 221 222 223 224 225
Acute Myocardial Infarction
Secondary prevention following acute MI† to reduce the risk of reinfarction and mortality.289 290
Acebutolol Hydrochloride Dosage and Administration
Individualize dosage according to patient response.1 2 4
β-Adrenergic blocking selectivity diminishes as dosage is increased.1
If long-term therapy is discontinued, reduce dosage gradually over a period of about 2 weeks.1 2 (See Abrupt Withdrawal of Therapy under Cautions.)
When substituting another β-blocker for acebutolol, initiate at a comparable dosage without interruption of β-blocker therapy.1 2
BP Monitoring and Treatment Goals
Carefully monitor BP during initial titration or subsequent upward adjustment in dosage.500 501
When available, use evidence-based dosing information (i.e., dosages shown in randomized controlled trials to reduce complications of hypertension) to determine target dosages; target dosages usually can be achieved within 2–4 weeks but may take up to several months.501
Goal is to achieve and maintain optimal control of BP; individualize specific target BP based on consideration of multiple factors, including patient age and comorbidities, and currently available evidence from clinical studies.500 501
Acebutolol hydrochloride is administered orally.1 2 Also been administered IV†,25 27 28 29 41 191 192 196 200 202 203 266 but a parenteral dosage form is currently not commercially available in the US.
Usually administer as a single daily dose;1 245 however, for 24-hour BP control, some patients may require administration of the daily dose in 2 divided doses.1 142 143 144 145 149 155 500
Twice-daily dosing of the drug appears to be more effective than once-daily dosing for the suppression and prevention of frequent VPCs.4 185 186 188 189 195 198 199 203 204 248
Once-daily administration may be as effective as divided doses;4 208 249 however, further studies are needed.4
Available as acebutolol hydrochloride; dosage expressed in terms of acebutolol.1
Initially, 200–400 mg daily.1 245 321 Usual maintenance dosage is 400–800 mg daily, 1 140 142 143 144 145 149 150 151 152 153 154 245 246 247 500 but some patients may achieve adequate BP control with dosages as low as 200 mg daily.1 4 500 Increase dosage up to 1.2 g daily in 2 divided doses in patients with more severe hypertension or if adequate reduction of BP does not occur;1 2 4 140 142 143 144 145 149 150 151 152 154 155 alternatively, add another hypotensive agent (e.g., thiazide diuretic).1 2 4 142 144 157 158 160 161 165 166 168
If intolerable adverse effects occur, consider dosage reduction; if adverse effects worsen or fail to resolve, may need to discontinue and switch to another antihypertensive drug class.501
Initially, 200 mg twice daily.1 187 196 Increase gradually until optimum effect is achieved.1 185 186 195 198 204 Usual maintenance dosage is 600–1200 mg daily.1 2 4 185 186 189 190 195 199 204
Initially, 200 mg twice daily.4 205 208 Increase dosage gradually until optimum effect is achieved.4 205 Usual maintenance dosage is 800 mg or less daily,4 206 207 208 209 210 211 212 213 214 but patients with severe angina may require higher dosages.4 205 209 211
Adjust dosage of β-blockers according to clinical response4 205 and to maintain a resting heart rate of 55–60 bpm.211 216
Maximum 1.2 g daily.1 2 4 140 142 143 144 145 149 150 151 152 154 155
Active metabolite (diacetolol) eliminated principally by the kidneys;1 123 125 dosage and/or frequency of administration must be modified in response to the degree of renal impairment.1 2 86 123 124 125 126 127
Reduction in Usual Daily Dosage
Acebutolol and diacetolol removed by hemodialysis;1 125 127 individualize dosage carefully in patients with severe renal impairment who undergo chronic intermittent hemodialysis.124 125
Consider reduction in maintenance dosage.1 2 Avoid dosages >800 mg daily.1 2
Cautions for Acebutolol Hydrochloride
Patients with heart block greater than first degree, severe bradycardia, cardiogenic shock, or overt cardiac failure.1
Possible precipitation of heart failure.1
Avoid use in patients with decompensated heart failure; use cautiously in patients with inadequate myocardial function and, if necessary, in patients with well-compensated heart failure (e.g., those controlled with cardiac glycosides and/or diuretics).1
Adequate treatment (e.g., with a cardiac glycoside and/or diuretic) and close observation recommended if signs or symptoms of impending cardiac failure occur; if cardiac failure continues, discontinue therapy, gradually if possible.1
Abrupt Withdrawal of Therapy
Possible exacerbated angina symptoms or precipitation of MI in patients with CAD.1 Abrupt discontinuance of therapy is not recommended.1 276 Gradually decrease dosage over a period of about 2 weeks; monitor patients carefully and advise to temporarily limit their physical activity.1 276 If exacerbation of angina occurs, reinstitute therapy promptly and initiate appropriate measures for the management of unstable angina pectoris.1
Peripheral Vascular Disease
Possible reduction in cardiac output and precipitation or aggravation of symptoms of arterial insufficiency.1 Use with caution; observe for evidence of disease progression.1
Use with caution in patients with bronchospastic disease; administer the lowest effective dosage (initially in divided doses). A bronchodilator (e.g., a β2-adrenergic agonist, theophylline) should be available for immediate use, if necessary.1
Possible risks associated with general anesthesia (e.g., severe hypotension, maintenance of heart beat) due to decreased ability of the heart to respond to reflex β-adrenergic stimuli.1 Use with caution in patients undergoing major surgery involving general anesthesia; anesthetics used should not cause myocardial depression.1
Diabetes and Hypoglycemia
Possible decreased signs and symptoms of hypoglycemia (e.g., tachycardia, palpitation, BP changes, tremor, feelings of anxiety, but not sweating or dizziness) and increased insulin-induced hypoglycemia.1
Use with caution in patients with diabetes mellitus.1
Signs of hyperthyroidism (e.g., tachycardia) may be masked.1 Possible thyroid storm if therapy is abruptly withdrawn; carefully monitor patients having or suspected of developing thyrotoxicosis.1
Patients with a history of anaphylactic reactions to a variety of allergens may be more reactive to repeated accidental, diagnostic, or therapeutic challenges with such allergens while taking β-blocking agents.1 Such patients may be unresponsive to usual doses of epinephrine.1
Distributed into milk in higher concentrations than in maternal plasma.1 2 105 Use not recommended by manufacturer.1
Safety and efficacy not established in children <12 years of age.1 268
Insufficient experience in patients >65 years of age to determine whether geriatric patients respond differently than younger adults.1 However, reduction of maintenance dosage may be necessary,1 2 since bioavailability of acebutolol and diacetolol (active metabolite) may be increased compared with that in younger adults.1 2 122 (See Geriatric Patients under Dosage and Administration.)
Use with caution.1 2 Cirrhosis does not appear to substantially affect the pharmacokinetics of acebutolol or diacetolol; however, the effects of hepatic impairment on elimination of the drug have not been fully evaluated.128
Use with caution; dosage should be reduced based on the degree of renal impairment.1 (See Renal Impairment under Dosage and Administration.)
Common Adverse Effects
Fatigue, dizziness, headache, dyspnea, constipation, diarrhea, dyspepsia, nausea, flatulence, insomnia, increased micturition, chest pain, edema, depression, abnormal dreams, rash, arthralgia, myalgia, cough, rhinitis, abnormal vision.1
Interactions for Acebutolol Hydrochloride
Possible exaggerated hypertensive reactions1
Warn patients of potential hazard1
Potential additive depressant effects on SA or AV nodal conduction318 319
Cardiac glycosides (digoxin)
Potential additive depressant effects on SA or AV nodal conduction318 319
Pharmacokinetic interaction unlikely1
Possible increased hypotensive effect1 2 142 144 157 158 160
Careful dosage adjustment recommended1 2 144 157 158 160
Possible decreased hypoglycemic action in type II diabetic patients, presumably by decreasing insulin secretion244
Pharmacokinetic interaction unlikely1
Pharmacokinetic interaction unlikely1
Possible increased hypotensive effect1 2 142 144 157 158 160
Careful dosage adjustment recommended1 2 144 157 158 160
Potential blunting of hypotensive effects1
Pharmacokinetic interaction unlikely1
Possible additive pharmacologic effects1
Observe closely for evidence of marked bradycardia or hypotension (e.g., vertigo, presyncope or syncope, or orthostatic changes in BP without compensatory tachycardia)1
Pharmacokinetic interaction unlikely1
Antagonism of β1-adrenergic stimulating effects (e.g., bronchodilation)1 2 57 58 59 62
Increased dosage of β-adrenergic agonist bronchodilators may be required 268 277
Acebutolol Hydrochloride Pharmacokinetics
Well absorbed from the GI tract following oral administration;1 2 4 11 91 109 undergoes extensive first-pass metabolism in the liver.1 2 97 99 109 122 124
Peak plasma acebutolol and diacetolol concentrations occur within 2–2.5 hours (range: 1–4 hours) and 4 hours (range: 2.4–5 hours), respectively, in healthy individuals1 2 94 95 97 98 99 126 135 or patients with hypertension91 or arrhythmias.2 90 137
Absolute bioavailability is approximately 35–50%.1 4 94 97 102
Food may slightly decrease the rate of absorption and peak plasma concentrations of acebutolol and its major metabolite (diacetolol), but the extent of absorption is not substantially affected.1 2 101
Effect on resting, reflex, or exercise-induced heart rate and systolic BP begins within 1–1.5 hours,1 3 21 91 100 in healthy1 21 98 100 or hypertensive91 individuals.
Effect may persist for up to 24 hours or longer.1 3 91 98 100
In geriatric patients, peak plasma concentrations and AUCs of acebutolol and diacetolol are increased twofold compared with those observed in younger patients.1 2 122
Acebutolol and diacetolol readily cross the placenta1 2 105 106 107 and can accumulate in the fetus.105 106 107
Acebutolol and diacetolol are distributed into milk at concentrations higher than those in maternal plasma. (See Lactation under Cautions.)1 2 105 106
Plasma Protein Binding
Approximately 11–25% (acebutolol) and 6–9% (diacetolol).2 93 103 Approximately 50% bound to erythrocytes.4 125
Rapidly and extensively metabolized in the liver2 110 113 to metabolites (acetolol and diacetolol).2 4 6 99 108 109 110 113
Acebutolol and its metabolites are excreted in feces and urine.1 87 92 109 111 123
About 3 hours in the initial distribution phase (t½α) 95 and about 11 hours (range: 6–12 hours) in the terminal phase (t½β).95 125 About 7.5 (range: 7–11 hours) and 3 hours, respectively, for diacetolol and acetolol following a single oral dose.101 108 125
Renal impairment may reduce clearances of acebutolol and diacetolol.125 Acebutolol and diacetolol are removed by hemodialysis.1 125 127
Tight containers1 253 at room temperature (approximately 25°C).1 2 3
Protect from light.1 305
Pharmacologic effects result from both the unchanged drug and diacetolol, 1 2 114 115 116 117 which is equipotent to acebutolol.1 2 114 115 116 117
Inhibits response to adrenergic stimuli by competitively blocking β1-adrenergic receptors within the myocardium.1 2 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 34 35 36 37 38 Blocks β2-adrenergic receptors within bronchial and vascular smooth muscle only at high doses.4 24 35 178
Decreases exercise-induced heart rate,1 2 4 11 12 13 23 24 25 27 inhibits reflex orthostatic tachycardia,1 2 4 11 12 13 23 24 and may decrease1 2 25 28 29 140 193 or leave unchanged 26 140 cardiac output at rest2 25 140 193 or during exercise.1 28 29 Decreases systolic and diastolic BP at rest1 2 13 19 23 56 57 139 and during exercise.1 2 155 160 171
Precise mechanism of hypotensive action has not been determined.7 22 26 34 35 139 178 May reduce BP by blocking peripheral (especially cardiac) adrenergic receptors (decreasing cardiac output), by decreasing sympathetic outflow from the CNS, and/or by suppressing renin release.7 26 34 35 140
Exhibits antiarrhythmic activity;1 2 137 185 186 187 188 189 190 193 194 195 196 199 204 considered a class II antiarrhythmic agent.254
Can produce nervous system effects,1 2 4 6 150 152 154 158 170 198 although the frequency and/or severity of such effects may be less than those observed with some other β-blockers.152 154 156 262
Unlike some β-blockers,147 148 does not consistently suppress plasma renin activity (PRA).26 71 139 140 141 142 143
May increase airway resistance and decrease ventilatory capacity,51 52 53 54 57 58 59 60 61 62 63 64 155 158 especially in patients with asthma and/or COPD or when high dosages are used.52 53 57 58 59 60 61 62 63 64 158 268
Does not appear to substantially affect glucose metabolism;73 75 however, the drug may potentiate insulin-induced hypoglycemia in diabetic patients receiving oral hypoglycemic agents.74 (See Interactions.)
Advice to Patients
Importance of taking acebutolol exactly as prescribed.1
Importance of not interrupting or discontinuing therapy without consulting clinician; patients should temporarily limit physical activity when discontinuing therapy.1 276
Importance of immediately informing clinician at the first sign or symptom of impending cardiac failure (e.g., weight gain, increased shortness of breath) or if any difficulty in breathing occurs.1
In patients with heart failure, importance of informing clinician of signs or symptoms of exacerbation (e.g., weight gain, difficulty in breathing).1
Importance of patients informing anesthesiologist or dentist that they are receiving acebutolol therapy prior to undergoing major surgery.1
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs as well as any concomitant illnesses.1
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.1
Importance of informing patients of other important precautionary information.1 (See Cautions.)
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
200 mg (of acebutolol)*
Acebutolol Hydrochloride Capsules
400 mg (of acebutolol)*
Acebutolol Hydrochloride Capsules
AHFS DI Essentials. © Copyright 2018, Selected Revisions February 28, 2017. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.
1. Wyeth-Ayerst Laboratories. Sectral (acebutolol hydrochloride) prescribing information. In: Physicians’ desk reference. 53rd ed. Montvale, NJ: Medical Economics Company Inc; 1999:3381-3.
2. Ives Laboratories Inc. Sectral product monograph. New York, NY; 1985 Mar.
3. Ives Laboratories Inc. Sectral product information form for American Hospital Formulary Service. Philadelphia, PA; 1985 Jan.
4. Singh BN, Thoden WR, Ward A. Acebutolol: a review of its pharmacological properties and therapeutic efficacy in hypertension, angina pectoris and arrhythmia. Drugs. 1985; 29:531-69.
5. Cowling CGD, Leary WP. Acebutolol: a review. Curr Ther Res. 1981; 30:765-74.
6. De Bono G, Kaye CM, Roland E et al. Acebutolol: ten years of experience. Am Heart J. 1985; 109(5 Part 2):1211-24.
7. Anon. Acebutolol. Med Lett Drugs Ther. 1985; 27:58-60.
8. Abernethy DR, Arendt RM, Greenblatt DJ. Pharmacologic properties of acebutolol: relationship of hydrophilicity to central nervous system penetration. Am Heart J. 1985; 109(5 Part 2):1120-5.
9. Ryan JR. Clinical pharmacology of acebutolol. Am Heart J. 1985; 109(5 Part 2):1131-6.
10. Mimnaugh MN, Gearien JE. Adrenergic drugs. In: Foye WO, ed. Principles of medicinal chemistry. 2nd ed. Philadelphia: Lea & Febiger; 1981:377-93.
11. Maxwell DR, Collins RF. Acebutolol (Sectral): I—review of the pharmacology and pharmacokinetics. Clin Trials J. 1974; 11(Suppl 3):9-18.
12. Basil B, Jordan R, Loveless AH et al. β-Adrenoceptor blocking properties and cardioselectivity of M & B 17,803A. Br J Pharmacol. 1973; 48:198-211.
13. Daly MJ, Flook JJ, Levy GP. The selectivity of β-adrenoceptor antagonists on cardiovascular and bronchodilator responses to isoprenaline in the anaesthetized dog. Br J Pharmacol. 1975; 53:173-81.
14. Harms HH. Isoproterenol antagonism of cardioselective beta adrenergic receptor blocking agents: a comparative study of human and guinea-pig cardiac and bronchial beta adrenergic receptors. J Pharmacol Exp Ther. 1976; 199:329-35.
15. Baird JRC, Linnell J. The assessment of β-adrenoceptor blocking potency and cardioselectivity in vitro and in vivo. J Pharm Pharmacol. 1972; 24:880-5.
16. Harms HH, Spoelstra AJG. Cardiac and bronchial β-adrenoceptor antagonistic potencies of atenolol, metoprolol, acebutolol, practolol, propranolol and pindolol in the anaesthetized dog. Clin Exp Pharmacol Physiol. 1978; 5:53-9.
17. Briant RH, Dollery CT, George CF. Cardiac and peripheral vascular beta-receptors in the dog and in man: the selectivity of acebutolol (Sectral). Clin Trials J. 1974; 11(Suppl 3):25-8.
18. Bilski A, Robertson HH, Wale JL. A study of the relationship between cardiac β-adrenoceptor blockade and intrinsic sympathomimetic activity in rats depleted of catecholamines. Clin Exp Pharmacol Physiol. 1979; 6:1-9.
19. Levy B. The selective beta receptor blocking properties of DL-1-(2-acetyl-4-n-butyramidophenoxy)-2-hydroxy-3- isopropylaminopropane-HCl (M&B 17803-A) in the anesthetized dog. J Pharmacol Exp Ther. 1973; 186:134-44.
20. Dreyer AC, Offermeier J. In vitro assessment of the selectivities of various beta-adrenergic blocking agents. Life Sci. 1980; 27:2087-92.
21. Cuthbert MF, Owusu-Ankomah K. Effect of M & B 17803A, a new β-adrenoceptor blocking agent, on the cardiovascular responses to tilting and to isoprenaline in man. Br J Pharmacol. 1971; 43:639-48.
22. Giacomini JC, Thoden WR. Ancillary pharmacologic properties of acebutolol: cardioselectivity, partial agonist activity, and membrane-stabilizing activity. Am Heart J. 1985; 109(5 Part 2):1137-44.
23. Wollam GL, Cody RJ Jr, Tarazi RC et al. Acute hemodynamic effects and cardioselectivity of acebutolol, practolol, and propranolol. Clin Pharmacol Ther. 1979; 25:813-20.
24. Mougeot G, Hugues FC, Julien D et al. Influence of propranolol and acebutolol on isoprenaline-induced changes in heart rate and peripheral blood flow in man. Arch Int Pharmacodyn Ther. 1981; 251:116-25.
25. Svendsen TL, Trap-Jensen J, C et al. Immediate central hemodynamic effects of five different beta-adrenoceptor-blocking agents, acebutolol, atenolol, pindolol, practolol, and propranolol, in patients with ischemic heart disease. Am Heart J. 1985; 109(5 Part 2):1145-50.
26. Dreslinski GR, Aristimuno GG, Messerli FH et al. Effects of beta blockade with acebutolol on hypertension, hemodynamics, and fluid volume. Clin Pharmacol Ther. 1979; 26:562-5.
27. Nigri A, Mangieri E, Martuscelli E et al. Acute hemodynamic effects of acebutolol and propranolol. Clin Ther. 1984; 6:693-8.
28. Dalal JJ, Ross PJ, Wong K et al. Acute effects of acebutolol on cardiovascular function in man. Br J Clin Pharmacol. 1981; 11:265-8.
29. Mason JW, Specter MJ, Ingels NB et al. Haemodynamic effects of acebutolol. Br Heart J. 1978; 40:29-34.
30. Lewis BS, Bakst A, Mitha AS et al. Haemodynamic effects of a new beta-blocking agent ″Sectral’ (M & B 17803A). Br Heart J. 1973; 35:743-51.
31. Ireland MA, Littler WA. The effects of oral acebutolol and propranolol on forearm blood flow in hypertensive patients. Br J Clin Pharmacol. 1981; 12:363-8.
32. Joye JA, Lee G, DeMaria AN et al. Afterload advantage of cardioselective beta blockade by acebutolol versus propranolol: hemodynamic assessment by cardiac catheterization in coronary patients. Circulation. 1978; 58:153.
33. Ablad B, Brogard M, C et al. β-Adrenergic receptor blocking properties of three allyl-substituted phenoxypropanolamines. Eur J Pharmacol. 1970; 13:59-64.
34. Prichard BNC. β-Adrenergic receptor blockade in hypertension, past, present and future. Br J Clin Pharmacol. 1978; 5:379-99.
35. Thadani U. Beta blockers in hypertension. Am J Cardiol. 1983; 52:10-5D.
36. Conolly ME, Kersting F, Dollery CT. The clinical pharmacology of beta-adrenoceptor-blocking drugs. Prog Cardiovasc Dis. 1976; 19:203-34.
37. Shand DG. State-of-the-art: comparative pharmacology of the β-adrenoceptor blocking drugs. Drugs. 1983; 25(Suppl 2):92-9.
38. Breckenridge A. Which beta blocker? Br Med J. 1983; 286:1085-8. (IDIS 169422)
39. Waal-Manning HHJ. The antihypertensive action of several β-adrenoceptor-blocking drugs. N Z Med J. 1976; 83:223-6.
40. LeClercq JF, Rosengarten MD, Kural S et al. Effects of intrinsic sympathetic activity of beta-blockers on SA and AV nodes in man. Eur J Cardiol. 1981; 12:367-75.
41. Marrott PK, Ruttley ST, Jenkins PM et al. The electrophysiological evaluation of intravenous acebutolol, a β-blocking drug. Eur J Cardiol. 1977; 6:117-30.
42. Amlie JP, Lessum S, Collins RF et al. Plasma levels and electrophysiological effects of acebutolol (M & B 17.803) in the dog heart in situ. Acta Pharmacol Toxicol. 1977; 40:378-88.
43. Kaul S, Hecht HS, Seidman R et al. Comparative effects of oral acebutolol and propranolol at rest and during exercise in ischemic heart disease: double-blind placebo crossover study utilizing radionuclide ventriculography. Am Heart J. 1984; 108:469-74.
44. Rochette L, Didier JP, Moreau D et al. Role of beta-adrenoceptor antagonism in the prevention of reperfusion ventricular arrhythmias: effects of acebutolol, atenolol, and d-propranolol on isolated working rat hearts subject to myocardial ischemia and reperfusion. Am Heart J. 1984; 107:1132-41.
45. Mason JW, Winkle RA, Meffin PJ et al. Electrophysiological effects of acebutolol. Br Heart J. 1978; 40:35-40.
46. Touboul P, Huerta F, Porte J et al. Etude des proprietes electrophysiologiques de l’acebutolol chez l’homme. (French; with English abstract.) Therapie. 1975; 30:417-27.
47. Chandraratna PAN, Aronow WS, Laddu A. Effects of acebutolol and propranolol on left ventricular performance assessed by echocardiography. Clin Pharmacol Ther. 1980; 27:460-3.
48. Katz RJ, DiBianco R, Singh S et al. Acebutolol and left ventricular function: assessment by radionuclide angiography. Clin Pharmacol Ther. 1981; 29:149-54.
49. Maclagan J, Ney UM. A comparison of the bronchoconstrictor and β-adrenoceptor blocking activity of propranolol and acebutolol. Br J Pharmacol. 1980; 68:196-8.
50. Wood AJJ. Pharmacologic differences between beta blockers. Am Heart J. 1984; 108:1070-7.
51. Kumana CR, Kaye CM, Leighton M et al. Cardiac and pulmonary effects of acebutolol. Lancet. 1975; 5:89-93.
52. Benson MK, Berrill WT, Cruickshank JM et al. A comparison of four β-adrenoceptor antagonists in patients with asthma. Br J Clin Pharmacol. 1978; 5:415-9.
53. Nair S, Maguire WC, Laddu AR. The effect of acebutolol, a beta adrenergic blocking agent, and placebo on pulmonary functions in asthmatics. Int J Clin Pharmacol Ther Toxicol. 1981; 19:519-26.
54. Gribbin HR, Mackay AD, Baldwin CJ et al. Bronchial and cardiac β-adrenoceptor blockade—a comparison of atenolol, acebutolol and labetalol. Br J Clin Pharmacol. 1981; 12:61-5.
55. Mue S, Sasaki T, Ohmi T et al. Influence of acebutolol on the haemodynamic and respiratory function of asthmatic patients. J Pharmacother. 1979; 2:67-71.
56. DiBianco R, Dickie KJ, Singh S et al. Pulmonary effects of acebutolol, a “cardioselective” beta adrenergic blocking agent. Int J Clin Pharmacol Ther Toxicol. 1982; 20:1-7.
57. Greefhorst APM, van Herwaarden CLA. Ventilatory and haemodynamic effects of terbutaline infusion during beta1-selective blockade with metoprolol and acebutolol in asthmatic patients. Eur J Clin Pharmacol. 1982; 23:203-8.
58. Whitsett TL, Levin DC, Manion CV. Comparison of the beta1 and beta2 adrenoceptor blocking properties of acebutolol and propranolol. Chest. 1982; 82:668-73.
59. Greefhorst APM, van Herwaarden CLA. Comparative study of the ventilatory effects of three beta1-selective blocking agents in asthmatic patients. Eur J Clin Pharmacol. 1981; 20:417-21.
60. Leary WP, Coleman AJ, Asmal AC. Respiratory effects of acebutolol hydrochloride: a new selective beta-adrenergic blocking agent. S Afr Med J. 1973; 47:1245-8.
61. Skinner C, Palmer KNV, Kerridge DF. Comparison of the effects of acebutolol (Sectral) and practolol (Eraldin) on airways obstruction in asthmatics. Br J Clin Pharmacol. 1975; 2:417-22.
62. Skinner C, Palmer KNV. Airways obstruction in asthmatic patients: comparison of the effects of acebutolol, practolol and placebo. Clin Trials J. 1974; 11:29-32.
63. Palmer KNV. Respiratory side effects of beta-blockers. Br Med J. 1977; 1:841.
64. Decalmer PBS, Chatterjee SS, Cruickshank JM et al. Beta-blockers and asthma. Br Heart J. 1978; 40:184-9.
65. Freed E. Acebutolol-controlled tachycardia in a depressed asthmatic. Med J Aust. 1980; 1:442.
66. Tattersfield AE, Harrison RN. Effect of β-blocker therapy on airway function. Drugs. 1983; 25(Suppl 2):227-31.
67. Gibbons DO, Lant AF, Ashford A et al. Comparative effects of acebutolol and practolol on the lipolytic response to isoprenaline. Br J Clin Pharmacol. 1976; 3:177-84.
68. Newman RJ. Comparison of propranolol, metoprolol, and acebutolol on insulin-induced hypoglycaemia. Br Med J. 1976; 2:447-9.
69. Lehtonen A. The effect of acebutolol on plasma lipids, blood glucose and serum insulin levels. Acta Med Scand. 1984; 216:57-60.
70. Grimaldi A, Bennett P, Delas B et al. β-Blockers and hypoglycaemia (assessment of cardioselective and intrinsic sympathomimetic properties in relation to severity of hypoglycaemia). Curr Ther Res. 1984; 36:361-73.
71. Covi G, Dalla Riva AD, Pomari S et al. Long-term treatment of essential hypertension with acebutolol: an evaluation of clinical and metabolic effects. Curr Ther Res. 1982; 31:1018-25.
72. Birnbaum J, DiBianco R, Becker KL et al. Glucose and lipid metabolism during acebutolol and propranolol therapy of angina in nondiabetic patients. Clin Pharmacol Ther. 1983; 33:294-300.
73. Frances Y, Luccioni R, Vague P et al. Effects of betaxolol, propranolol, and acebutolol on the glycoregulation after oral glucose tolerance test in hypertensive patients. In: Morselli PL, ed. LERS monograph series. Vol 1. New York: Raven Press; 1983:213-20.
74. Deacon SP, Karunanayake A, Barnett D. Acebutolol, atenolol, and propranolol and metabolic responses to acute hypoglycaemia in diabetics. Br Med J. 1977; 2:1255-7.
75. Koch G, Franz IW, Gubba A et al. β-Adrenoceptor blockade and physical activity: cardiovascular and metabolic aspects. Acta Med Scand. 1983; 672(Suppl):55-62.
76. Barnett AH, Leslie D, Watkins PJ. Can insulin-treated diabetics be given beta-adrenergic blocking drugs? Br Med J. 1980; 280:976-8.
77. Leary WP. The cardioselectivity of acebutolol (Sectral) in man. Clin Trials J. 1974; 11(Suppl 3):33-5.
78. James I. The beta-blocker dilemma. Geriatric Med. 1983; 13:429-30.
79. Giuntoli F, Scalabrino A, Galeone F et al. Antihypertensive and metabolic effects of a long-term treatment with acebutolol. Curr Ther Res. 1984; 36:188-94.
80. Newman RJ. Comparison of the antilipolytic effect of metoprolol, acebutolol, and propranolol in man. Br Med J. 1977; 2:601-3.
81. Lehtonen A. Effect of beta blockers on blood lipid profile. Am Heart J. 1985; 109(5 Part 2):1192-6.
82. Harms HH, Gooren L, Spoelstra AJG et al. Blockade of isoprenaline-induced changes in plasma free fatty acids, immunoreactive insulin levels and plasma renin activity in healthy human subjects, by propranolol, pindolol, practolol, atenolol, metoprolol and acebutolol. Br J Clin Pharmacol. 1978; 5:19-26.
83. Lewis MJ, Groom GV, Barber R et al. The effects of propranolol and acebutolol on the overnight plasma levels of anterior pituitary and related hormones. Br J Clin Pharmacol. 1981; 12:737-42.
84. Jones MK, John R, Jones GR. The effect of oxprenolol, acebutolol and propranolol on thyroid hormones in hyperthyroid subjects. Clin Endocrinol. 1980; 13:343-7.
85. Collett JT, Hendrickson JA, Chew YC et al. Comparative beta-blocking potencies of acebutolol and propranolol relative to plasma drug levels. Int J Clin Pharmacol Ther Toxicol. 1981; 19:473-8.
86. de Villiers AS, Folb PI, Pascoe M et al. Pharmacokinetics of acebutolol and its acetyl metabolite, diacetolol, in hypertensive patients and in renal use. S Afr J Sci. 1981; 77:286.
87. George CF, Gruchy BS. Elimination of drugs by active intestinal transport. J Pharm Pharmacol. 1979; 31:643-4.
88. Cockburn JJ. Which beta blocker? Br Med J. 1983; 286:1439. Letter.
89. Feely J, Maclean D. New drugs: beta blockers and sympathomimetics. BMJ. 1983; 286:1972.
90. Winkle RA, Meffin PJ, Ricks WB et al. Acebutolol metabolite plasma concentration during chronic oral therapy. Br J Clin Pharmacol. 1977; 4:519-22.
91. Martin MA, Phillips FC, Tucker GT et al. Acebutolol in hypertension: relationships between drug concentration and effects. Eur J Clin Pharmacol. 1978; 14:383-90.
92. Kaye CM. The biliary excretion of acebutolol in man. J Pharm Pharmacol. 1976; 28:449-50.
93. Meffin PJ, Winkle RA, Peters FA et al. Acebutolol disposition after intravenous administration. Clin Pharmacol Ther. 1977; 22:557-67.
94. Meffin PJ, Winkle RA, Peters FA et al. Dose-dependent acebutolol disposition after oral administration. Clin Pharmacol Ther. 1978; 24:542-7.
95. Gulaid AA, James IM, Kaye CM et al. The pharmacokinetics of acebutolol in man, following the oral administration of acebutolol HCl as a single dose (400 mg), and during and after repeated oral dosing (400 mg, b.d.) Biopharm Drug Dispos. 1981; 2:103-14.
96. de Soyza ND, Murphy ML, O’Riley M et al. Correlation of antiarrhythmic activity of acebutolol with blood levels and heart rate. Clin Pharmacol Ther. 1982; 31:217.
97. Roux A, Flouvat B, Fouache Y et al. Systemic bioavailability of acebutolol in man. Biopharm Drug Dispos. 1983; 4:293-7.
98. Cuthbert MF, Collins RF. Plasma levels and β-adrenoceptor blockade with acebutolol, practolol and propranolol in man. Br J Clin Pharmacol. 1975; 2:49-55.
99. Meffin PJ, Harapat SR, Harrison DC. Quantitation in plasma and urine of acebutolol and a major metabolite with preliminary observations on their disposition kinetics in man. Res Commun Chem Pathol Pharmacol. 1976; 15:31-51.
100. Watson RDS, Littler WA. Onset and duration of β-adrenergic receptor blockade following single oral dose acebutolol hydrochloride (Sectral). Br J Clin Pharmacol. 1979; 7:557-61.
101. Zaman R, Wilkins MR, Kendall MJ et al. The effect of food and alcohol on the pharmacokinetics of acebutolol and its metabolite, diacetolol. Biopharm Drug Dispos. 1984; 5:91-5.
102. Kaye CM, Kumana CR, Leighton M et al. Observations on the pharmacokinetics of acebutolol. Clin Pharmacol Ther. 1976; 19:416-20.
103. Coombs TJ, Coulson CJ, Smith VJ. Blood plasma binding of acebutolol and diacetolol in man. Br J Clin Pharmacol. 1980; 9:395-7.
104. Zaman R, Jack DB, Kendall MJ. The penetration of acebutolol and its major metabolite, diacetolol, into human cerebrospinal fluid and saliva. Br J Clin Pharmacol. 1981; 12:427-9.
105. Bianchetti G, Boutroy MJ, Dubruc C et al. Placental transfer and pharmacokinetics of acebutolol and N-acetyl acebutolol in the newborn. Br J Pharmacol. 1981; 72:135-6P.
106. Bianchetti G, Dubruc C, Vert P et al. Placental transfer and pharmacokinetics of acebutolol in newborn infants. Clin Pharmacol Ther. 1981; 29:233-4.
107. Daffos F, Freund M, Sarrot G et al. Passage transplacentaire de l’acebutolol et du diacetolol. Nouv Presse Med. 1982; 11:2154-5.
108. Alexander MS, Bianchine JR. Acebutolol kinetics following oral and intravenous administration in man. Clin Pharmacol Ther. 1984; 35:225.
109. Gabriel R, Kaye CM, Sankey MG. Preliminary observations on the excretion of acebutolol and its acetyl metabolite in the urine and faeces of man. J Pharm Pharmacol. 1981; 33:386-7.
110. Andresen BD, Davis FT. Metabolism of acebutolol-d6 in the rat correlates with the identification of a new metabolite in human urine. Drug Metab Dispos. 1979; 79:360-5.
111. Collins RF, George CF. Studies on the disposition and fate of [14C]-acebutolol in man and dog. Br J Clin Pharmacol. 1976; 3:346-7P.
112. Roux A, Flouvat B, Chau NP et al. Pharmacokinetics of acebutolol after intravenous bolus administration. Br J Clin Pharmacol. 1980; 9:215-7.
113. Gulaid A, James IM, Kaye CM et al. Lack of correlation between acetylator status and the production of the acetyl metabolite of acebutolol in man. Br J Clin Pharmacol. 1978; 5:261-2.
114. Basil B, Jordan R. Pharmacological properties of diacetolol (M&B 16,942), a major metabolite of acebutolol. Eur J Pharmacol. 1982; 80:47-56.
115. Thomas MS, Tattersfield AE. Comparison of beta-adrenoceptor selectivity of acebutolol and its metabolite diacetolol with metoprolol and propranolol in normal man. Eur J Clin Pharmacol. 1986; 29:679-83.
116. Ohashi K, Warrington SJ, Kaye CM et al. Observations on the clinical pharmacology and plasma concentrations of diacetolol, the major human metabolite of acebutolol. Br J Clin Pharmacol. 1981; 12:561-5.
117. Flouvat B, Roux A, Delhotal B et al. The beta-blocking effect of diacetolol in humans and its relationship to plasma levels. Int J Clin Pharmacol Ther Toxicol. 1982; 20:358-61.
118. Flouvat B, Roux A, Chau NP et al. Pharmacokinetics and bioavailability of diacetolol, the main metabolite of acebutolol. Eur J Clin Pharmacol. 1981; 19:287-92.
119. Kaye CM. New drugs: beta blockers and sympathomimetics. BMJ. 1983; 286:1439.
120. Feely J, deVane PJ, Maclean D. Beta-blockers and sympathomimetics. BMJ. 1983; 286:1043-7.
121. Kaye CM, Long AD. The influence of pH on the buccal absorption and plasma and renal elimination of acebutolol. Br J Clin Pharmacol. 1976; 3:196-7.
122. Roux A, Henry JF, Fouache Y et al. A pharmacokinetic study of acebutolol in aged subjects as compared to young subjects. Gerontology. 1983; 29:202-8.
123. Munn S, Bailey RR, Begg E et al. Plasma and urine concentrations of acebutolol and its acetyl metabolite in patients with renal functional impairment. N Z Med J. 1980; 91:289-91.
124. Kirch W, Kohler H, Berggren G et al. The influence of renal function on plasma levels and urinary excretion of acebutolol and its main N-acetyl metabolite. Clin Nephrol. 1982; 18:88-94.
125. Roux A, Aubert P, Guedon J et al. Pharmacokinetics of acebutolol in patients with all grades of renal failure. Eur J Clin Pharmacol. 1980; 17:339-48.
126. Kaye CM, Dufton JF. Preliminary observations on the elimination of acebutolol in severe chronic renal failure. Br J Clin Pharmacol. 1976; 3:198-9.
127. Smith RS, Warren DJ, Renwick AG et al. Acebutolol pharmacokinetics in renal failure. Br J Clin Pharmacol. 1983; 16:253-8.
128. Zaman R, Jack DB, Wilkins MR et al. Lack of effect of liver disease on the pharmacokinetics of acebutolol and diacetolol: a single dose study. Biopharm Drug Dispos. 1985; 6:131-7.
129. Esler M, Zweifler A, Randall O et al. Pathophysiologic and pharmacokinetic determinants of the antihypertensive response to propranolol. Clin Pharmacol Ther. 1978; 22:299-308.
130. Collste P, Haglund K, Frisk-Holmberg M et al. Pharmacokinetics and pharmacodynamics of alprenolol in the treatment of hypertension. Eur J Clin Pharmacol. 1976; 10:89-95.
131. Gibson TP, Matusik E, Nelson LD et al. Artificial kidneys and clearance calculations. Clin Pharmacol Ther. 1976; 20:720-6.
132. Pond S, Rosenberg J, Benowitz NL et al. Pharmacokinetics of haemoperfusion for drug overdose. Clin Pharmacokinet. 1979; 4:329-54.
133. Lee CSC, Marbury TC. Drug therapy in patients undergoing haemodialysis: clinical pharmacokinetic considerations. Clin Pharmacokinet. 1984; 9:42-66.
134. Pond SM. Renal principles: diuresis, dialysis, and hemoperfusion. In: Goldfrank’s toxicologic emergencies. 3rd ed. Norwalk, CT: Appleton-Century-Crofts; 1986:102-15.
135. Jack DB, Quarterman CP, Zaman R et al. Variability of beta-blocker pharmacokinetics in young volunteers. Eur J Clin Pharmacol. 1982; 23:37-42.
136. Tjandramaga TB. Altered pharmacokinetics of β-adrenoceptor blocking drugs in patients with renal insufficiency. Arch Int Pharmacodyn Ther. 1980; 247(Suppl):38-53.
137. Gradman AH, Winkle RA, Fitzgerald JW et al. Suppression of premature ventricular contractions by acebutolol. Circulation. 1977; 55:785-91.
138. DiBianco R, Singh SN, Shah PM et al. Comparison of the antianginal efficacy of acebutolol and propranolol. Circulation. 1982; 65:119-28.
139. Fournier A, Hardin JM, Alexandre JM et al. Anti-hypertensive effect of acebutolol: its relation to sympathetic nervous system responsiveness and to plasma renin and dopamine-β-hydroxylase activities. Clin Sci Mol Med. 1976; 51:477-80s.
140. Martin MA, Phillips CA, Smith AJ. Acebutolol in hypertension—a double-blind trial against placebo. Br J Clin Pharmacol. 1978; 6:351-6.
141. Menard J, Bertagna X, N’Guyen PT et al. Rapid identification of patients with essential hypertension sensitive to acebutolol (a new cardioselective beta-blocker). Am J Med. 1976; 60:886-90.
142. Belleau LJ, Lebel M, Brossard JJ. Merits of adding a beta blocker (acebutolol) to a diuretic (hydrochlorothiazide) in the treatment of hypertension. J Clin Pharmacol. 1982; 22:20-7.
143. Alhenc-Gelas F, Plouin PF, Ducrocq MB et al. Comparison of the antihypertensive and hormonal effects of a cardioselective beta-blocker, acebutolol, and diuretics in essential hypertension. Am J Med. 1978; 64:1005-12.
144. Gorkin JU, Elijovich F, Dziedzic SW et al. Addition of acebutolol to diuretics in hypertension. Clin Pharmacol Ther. 1981; 30:739-44.
145. Thibonnier M, Lardoux MD, Corvol P. Comparative trial of labetalol and acebutolol, alone or associated with dihydralazine, in treatment of essential hypertension. Br J Clin Pharmacol. 1980; 9:561-7.
146. Begg E, Munn S, Bailey RR. Acebutolol in the treatment of patients with hypertension and renal functional impairment. N Z Med J. 1979; 89:293-5.
147. Heel RC, Brogden RN, Speight TM et al. Atenolol: a review of its pharmacological properties and therapeutic efficacy in hypertension. Drugs. 1979; 17:425-60.
148. Merck Sharp & Dohme. Blocadren prescribing information. West Point, PA; 1985 Apr.
149. Gabriel R. Acebutolol in the management of hypertension in patients with renal disease. Br J Clin Pract. 1979; 33:259-62.
150. Wahl J, Singh BN, Thoden WR. Comparative hypotensive effects of acebutolol and hydrochlorothiazide in patients with mild to moderate essential hypertension: a double-blind multicenter evaluation. Am Heart J. 1986; 111:353-62.
151. Hansson L, Berglund G, Andersson O et al. Controlled trial of acebutolol in hypertension. Eur J Clin Pharmacol. 1977; 12:89-92.
152. Wahl J, Turlapaty P, Singh BN et al. Comparison of acebutolol and propranolol in essential hypertension. Am Heart J. 1985; 109:313-21.
153. Singh AN, Paul L, Brossard JJ. Double-blind cross-over study of two beta-blocking agents acebutolol and propranolol in essential hypertension. Curr Ther Res. 1980; 28:964-71.
154. Davidov M. Acebutolol in essential hypertension: results of two multicenter studies against placebo and propranolol. Am Heart J. 1985; 109(5 Part 2):1158-67.
155. Manttari M, Eisalo A. A comparison of two cardioselective beta-blockers with different ancillary properties in the treatment of hypertension. Acta Med Scand. 1982; 668(Suppl):114-7.
156. Turner AS, Brocklehurst JC. Once-daily acebutolol and atenolol in essential hypertension: double-blind crossover comparison. Am Heart J. 1985; 109(5 Part 2):1178-83.
157. Hua ASP, Kalowski S, Whitworth JA et al. Acebutolol in mild to moderate hypertension. Med J Aust. 1980; 1:226-8.
158. Baker PG, Goulton J. A multicentre study of a once daily dosage of acebutolol in the treatment of hypertension in general practice. J Int Med Res. 1979; 7:201-14.
159. Nadeau J, Ogilvie RI, Ruedy J et al. Acebutolol and hydrochlorothiazide in essential hypertension. Clin Pharmacol Ther. 1980; 28:296-301.
160. Franz IW. Differential antihypertensive effect of acebutolol and hydrochlorothiazide/amiloride hydrochloride combination on elevated exercise blood pressures in hypertensive patients. Am J Cardiol. 1980; 46:301-5.
161. Leary WP, Asmal AC, Williams PC. Aldactone and acebutolol in treatment of hypertension. J Int Med Res. 1979; 7:29-32.
162. Khalil SI, El Zein O, Bella ME. A double-blind, crossover study of acebutolol and hydrochlorothiazide/amiloride diuretic in Sudanese patients with essential hypertension. Curr Med Res Opin. 1982; 8:39-43.
163. Oli JM. Acebutolol in the management of hypertension in Nigerians. Curr Ther Res. 1981; 30:477-82.
164. MacGregor GA, Banks RA, Markandu ND et al. Lack of effect of beta-blocker on flat dose response to thiazide in hypertension: efficacy of low dose thiazide combined with beta-blocker. BMJ. 1983; 286:1535-8.
165. Nievel JG, Havard CWH. Assessment of the efficacy and acceptability of an acebutolol/hydrochlorothiazide combination in the treatment of mild to moderate essential hypertension. Curr Med Res Opin. 1981; 7:526-35.
166. Mitenko PA, McKenzie JK, Brossard JJ. Antihypertensive action of acebutolol (Sectral) when used concomitantly with hydrochlorothiazide. Br J Clin Pharmacol. 1982; 13:209-12.
167. Ogilvie RI, Nadeau JH. Cardiovascular effects of acebutolol and hydrochlorothiazide in essential hypertension. Hypertension. 1982; 4:320-4.
168. Down PF, Rao SK, Braverman AM et al. Treatment of hypertension in the elderly with a low dose combination of a beta-adrenoceptor blocker and a thiazide diuretic: comparison with methyldopa. Br J Clin Pract. 1983; 37:371-4,88.
169. Fraser DM, Nimmo GR, Poloniecki JD. Acebutolol in the treatment of diabetic patients with hypertension. Curr Med Res Opin. 1986; 10:122-7.
170. Boyles PW. Effects of age and race on clinical response to acebutolol in essential hypertension. Am Heart J. 1985; 109(5 Part 2):1184-92.
171. Costa FV, Caldari R, Borghi C et al. Acebutolol, atenolol and nadolol: comparison of their antihypertensive efficacy at rest and during exercise. Curr Ther Res. 1984; 35:961-73.
173. Anon. Drugs for hypertension. Med Lett Drugs Ther. 1984; 26:107-12.
174. Moser M. Initial treatment of adult patients with essential hypertension. Part I: why conventional stepped-care therapy of hypertension is still indicated. Pharmacotherapy. 1985; 5:189-95.
175. Kaplan NM. Initial treatment of adult patients with essential hypertension. Part II: alternating monotherapy is the preferred treatment. Pharmacotherapy. 1985; 5:195-200.
176. World Health Organization/International Society of Hypertension Fourth Mild Hypertension Conference. 1986 guidelines for the treatment of mild hypertension: memorandum from the WHO/ISH. Hypertension. 1986; 8:957-61.
178. Weiner N. Drugs that inhibit adrenergic nerves and block adrenergic receptors. In: Gilman AG, Goodman LS, Rall TW et al, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 7th ed. New York: Macmillan Publishing Company; 1985:181-214.
179. Rudd P, Blaschke TF. Antihypertensive agents and the drug therapy of hypertension. In: Gilman AG, Goodman LS, Rall TW et al, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 7th ed. New York: Macmillan Publishing Company; 1985:784-805.
180. Kaplan NM. Mild hypertension: when and how to treat. Arch Intern Med. 1983; 143:255-9.
181. Kaplan NM. Non-drug treatment of hypertension. Ann Intern Med. 1985; 102:359-73.
182. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Return of elevated blood pressure after withdrawal of antihypertensive drugs. Circulation. 1975; 51:1107-13.
183. Kaplan NM. New choices for the initial drug therapy of hypertension. Am J Cardiol. 1983; 51:1786-8.
184. Lewis JE. Comparison of acebutolol and hydrochlorothiazide in essential hypertension. Am Heart J. 1985; 109(5 Part 2):1168-74.
185. de Soyza N, Shapiro W, Chandraratna PAN et al. Acebutolol therapy for ventricular arrhythmia: a randomized, placebo-controlled, double-blind multicenter study. Circulation. 1982; 65:1129-33.
186. Lui HK, Lee G, Dhurandhar R et al. Reduction of ventricular ectopic beats with oral acebutolol: a double-blind, randomized crossover study. Am Heart J. 1983; 105:722-6.
187. Burckhardt D, Raeder EA. The effect of acebutolol on cardiac arrhythmias in patients with chronic coronary artery disease. Am Heart J. 1980; 99:443-5.
188. Peretz DI, McMurtry TJ. Evaluation of the clinical effectiveness of acebutolol, a cardio-specific beta-adrenergic blocking agent, in the suppression of premature ventricular contractions. Curr Ther Res. 1979; 26:557-61.
189. Singh SN, DiBianco R, Davidov ME et al. Comparison of acebutolol and propranolol for treatment of chronic ventricular arrhythimia: a placebo-controlled, double-blind, randomized crossover study. Circulation. 1982; 65:1356-64.
190. Shapiro W, Park J, Koch GG. Variability of spontaneous and exercise-induced ventricular arrhythmias in the absence and presence of treatment with acebutolol or quinidine. Am J Cardiol. 1982; 49:445-54.
191. Labram C. Control of cardiac arrhythmias: the use of acebutolol. Clin Trials J. 1974; 3:115-20.
192. Williams DO, Tatelbaum R, Most AS. Effective treatment of supraventricular arrhythmias with acebutolol. Am J Cardiol. 1979; 44:521-5.
193. Ahumada GG, Karlsberg RP, Jaffe AS et al. Reduction of early ventricular arrhythmia by acebutolol in patients with acute myocardial infarction. Br Heart J. 1979; 41:654-9.
194. de Soyza N, Kane JJ, Murphy ML et al. The long-term suppression of ventricular arrhythmia by oral acebutolol in patients with coronary artery disease. Am Heart J. 1980; 100:631-8.
195. de Soyza N. Acebutolol for premature ventricular contractions: short- and long-term effects. Am Heart J. 1985; 109(5 Part 2):1205-9.
196. Khambatta RB. Clinical tachydysrhythmias: the effect of acebutolol (Sectral) on tachydysrhythmias in general and after myocardial infarction. Clin Trials J. 1971; 11:109-14.
197. Aronow WS, Turbow M, Lurie M et al. Treatment of premature ventricular complexes with acebutolol. Am J Cardiol. 1979; 43:106-8.
198. Chandraratna PAN. Comparison of acebutolol with propranolol, quinidine, and placebo: results of three multicenter arrhythmia trials. Am Heart J. 1985; 109(5 Part 2):1198-204.
199. Glasser SP, Clark PI, Laddu AR. Comparison of the antiarrhythmic effects of acebutolol and propranolol in the treatment of ventricular arrhythmias. Am J Cardiol. 1983; 52:992-5.
200. Aronow WS, Van Camp S, Turbow M et al. Acebutolol in supraventricular arrhythmias. Clin Pharmacol Ther. 1979; 25:149-53.
201. Aronow WS, Wong R, Plasencia G et al. Effect of acebutolol and propranolol on premature ventricular complexes. Clin Pharmacol Ther. 1980; 28:28-31.
202. Letac B. Treatment of cardiac arrhythmias: use of intravenous acebutolol. Clin Trials J. 1974; 11:105-8.
203. Gotsman MS, Lewis BS, Mitha AS. Acebutolol (Sectral) in the treatment of cardiac arrhythmias. Clin Trials J. 1974; 11:121-6.
204. Platia EV, Berdoff R, Stone G et al. Comparison of acebutolol and propranolol therapy for ventricular arrhythmias. J Clin Pharmacol. 1985; 25:130-7.
205. DiBianco R, Singh S, Singh JB et al. Effects of acebutolol on chronic stable angina pectoris: a placebo-controlled, double-blind, randomized crossover study. Circulation. 1980; 62:1179-87.
206. Lee G, DeMaria AN, Favrot L et al. Efficacy of acebutolol in chronic stable angina using single-blind and randomized double-blind protocol. J Clin Pharmacol. 1982; 22:371-8.
207. Tremblay G, Biron P, Proulx A. Acebutolol: efficacy of a single daily dose in angina pectoris. Curr Ther Res. 1979; 25:637-40.
208. Tremblay G, Biron P, Caille G et al. Double-blind crossover trial of single- versus twice-daily doses of acebutolol in angina. Curr Ther Res. 1981; 29:644-50.
209. Rod JL, Admon D, Kimchi A et al. Evaluation of the beta-blocking drug acebutolol in angina pectoris. Am Heart J. 1979; 98:604-12.
210. Macdonald IL, Culbert PS, Robertson JW et al. A comparison study of acebutolol, a cardiospecific β-adrenergic blocker, and propranolol in the treatment of angina pectoris. Curr Ther Res. 1978; 24:470-8.
211. DiBianco R, Singh SN, Shah PM et al. Comparison of the antianginal efficacy of acebutolol and propranolol: a multicenter, randomized, double-blind placebo-controlled study. Circulation. 1982; 65:1119-28.
212. Ross MB, Levine P. A double-blind cross-over evaluation of acebutolol and propranolol in patients with angina pectoris. Curr Ther Res. 1981; 29:202-7.
213. Biron P, Tremblay G, Proulx A. Double-blind crossover comparison of acebutolol and propranolol in angina. Clin Pharmacol Ther. 1978; 23:109.
214. Rotem CE, Carruthers J, Byrne A. Long-term management of angina pectoris with acebutolol. Curr Ther Res. 1979; 26:562-7.
215. Frishman WH. β-Adrenoceptor antagonists: new drugs and new indications. N Engl J Med. 1981; 305:500-6.
216. Opie LH. Drugs and the heart. Lancet. 1980; 1:693-8.
217. Leonard RG, Talbert RL. Calcium-channel blocking agents. Clin Pharm. 1982; 1:17-33.
218. K.dtdberg RP. Calcium channel blockers for cardiovascular disorders. Arch Intern Med. 1982; 142:452-5.
219. Zelis R. Calcium-blocker therapy for unstable angina pectoris. N Engl J Med. 1982; 306:926-8.
220. Biron P, Tremblay G. Differential antianginal responsiveness to acebutolol. Eur J Clin Pharmacol. 1975; 8:15-9.
221. Kimchi A, Gotsman MS, Lewis BS. Acebutolol in angina pectoris: objective assessment using graded treadmill testing. Isr J Med Sci. 1978; 14:941-7.
222. Gotsman MS, Lewis BS. The treatment of angina pectoris: an objective assessment of oral acebutolol (Sectral). Clin Trials J. 1974; 11(Suppl 3):80-5.
223. Pfisterer M, Muller-Brand J, Burkart F. Combined acebutolol/nifedipine therapy in patients with chronic coronary artery disease: additional improvement of ischemia-induced left ventricular dysfunction. Am J Cardiol. 1982; 49:1259-66.
224. Steele P, Gold F. Favorable effects of acebutolol on exercise performance and angina in men with coronary artery disease. Chest. 1982; 82:40-3.
225. De Ponti C, De Biase AM, Cataldo G et al. Effects of nifedipine, acebutolol, and their association on exercise tolerance in patients with effort angina. Cardiology. 1981; 68(Suppl 2):195-9.
226. Geigy Pharmaceuticals. Lopressor prescribing information. In: Huff BB, ed. Physicians’ desk reference. 41st ed. Oradell, NJ: Medical Economics Company Inc; 1987:956-60.
227. Booth RJ, Wilson JD, Bullock JY. β-Adrenergic-receptor blockers and antinuclear antibodies in hypertension. Clin Pharmacol Ther. 1982; 31:555-63.
228. Akoun GM, Herman DP, Mayaud CM et al. Acebutolol-induced hypersensitivity pneumonitis. BMJ. 1983; 286:266-7.
229. Akoun GM, Mayaud CM, Milleron BJ et al. Drug-related pneumonitis and drug-induced hypersensitivity pneumonitis. Lancet. 1984; 1:1362.
230. Cody RJ Jr, Calabrese LH, Clough JD et al. Development of antinuclear antibodies during acebutolol therapy. Clin Pharmacol Ther. 1979; 25:800-5.
231. Tirlapur VG, Evans PJ, Jones MK. Shock syndrome after acebutolol. Br J Clin Pract. 1986; 40:33-4.
232. Piette JC, Bourgeois P, Herson S et al. Acebutolol-induced lupus (AIL). Arthritis Rheum. 1985; 28(Suppl 4S):S52.
233. Record NB Jr. Acebutolol-induced pleuropulmonary lupus syndrome. Ann Intern Med. 1981; 95:326-7.
234. Wood GM, Bolton RP, Muers MF et al. Pleurisy and pulmonary granulomas after treatment with acebutolol. BMJ. 1982; 285:936.
235. Leggett RJE. Pleurisy and pulmonary granulomas after treatment with acebutolol. BMJ. 1982; 285:1425.
236. Lyall MG, Bainbridge JG, Khambatta RB. Ophthalmological monitoring of patients receiving long-term acebutolol. Br J Clin Pharmacol. 1983; 16:574-6.
237. Welsh N, Leary WP, Van Der Byl K. Acebutolol: prolonged administration without ophthalmological complications. Curr Ther Res. 1983; 33:611-5.
238. Martin DE, Kammerer WS. The hypertensive surgical patient: controversies in management. Surg Clin North Am. 1983; 63:1017-33.
239. Dumez Y, Chobroutsky C, Hornych H et al. Neonatal effects of maternal administration of acebutolol. BMJ. 1981; 283:1077-9.
240. Williams ER, Morrissey JR. A comparison of acebutolol with methyldopa in hypertensive pregnancy. Pharmatherapeutica. 1983; 3:487-91.
241. Dubois D, Petitcolas J, Temperville B et al. Treatment of hypertension in pregnancy with β-adrenoceptor antagonists. Br J Clin Pharmacol. 1982; 13(Suppl):375-8S.
242. Lewis M, Kallenbach J, Germond C et al. Survival following massive overdose of adrenergic blocking agents (acebutolol and labetalol). Eur Heart J. 1983; 4:328-32.
243. Sangster B, de Wildt D, van Dijk A. A case of acebutolol intoxication. J Toxicol Clin Toxicol. 1983; 20:69-77.
244. Zaman R, Kendall MJ. The effect of acebutolol and propranolol on the hypoglycaemic action of glibenclamide. Br J Clin Pharmacol. 1982; 13:507-12.
245. Ashton WL. An open, multicentre study of acebutolol, given as a single daily dose, in the management of hypertension. Curr Med Res Opin. 1977; 5:279-83.
246. Ashton WL. Acebutolol (400 mg) given as a single daily dose to hypertensive patients previously stabilized on 400 mg acebutolol daily in divided doses: an open multicentre study. Curr Med Res Opin. 1978; 5:347-53.
247. Watson RDS, Stallard TJ, Littler WA. Comparison of once and twice daily administration of acebutolol in hypertension. Br J Clin Pharmacol. 1980; 9:209-12.
248. Frick MH, Kala R. Antiarrhythmic significance of dosing intervals in beta receptor blocking therapy of hypertension with acebutolol. Am J Cardiol. 1981; 48:911-6.
249. Klug E, Schneider V. Todliche Vergiftung mit Acebutolol (Prent). (German; with English abstract.) Z Rechtsmed. 1979; 83:325-30.
250. Beyer H, Blank P, Kelch L et al. Letale Vergiftung mit Acebutolol. (German; with English abstract.) Intensivmed Prax. 1981; 18:83-5.
251. Cruickshank JM. The clinical importance of cardioselectivity and lipophilicity in beta blockers. Am Heart J. 1980; 100:160-78.
252. Woods PB, Robinson ML. An investigation of the comparative liposolubilities of β-adrenoceptor blocking agents. J Pharm Pharmacol. 1981; 33:172-3.
253. The United States pharmacopeia, 24th rev, and The national formulary, 19th ed. Rockville, MD: The United States Pharmacopeial Convention, Inc; 2000:15.
254. Bigger JT Jr, Hoffman BF. Antiarrhythmic drugs. In: Gilman AG, Goodman LS, Rall TW et al, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 7th ed. New York: Macmillan Publishing Company; 1985:748-83.
255. Chatterji AN. A randomized crossover comparison of acebutolol and methyldopa in the treatment of mild to moderate essential hypertension. Curr Med Res Opin. 1978; 5:675-81.
256. Anon. Drugs for cardiac arrhythmias. Med Lett Drugs Ther. 1986; 28:111-6.
257. Gosselin RE, Smith RP, Hodge HC. Clinical toxicology of commercial products. 5th ed. Baltimore: Williams & Wilkins; 1984:I-8.
258. Frishman W, Jacob H, Eisenberg E et al. Clinical pharmacology of the new β-adrenergic blocking drugs. Part 8. Self-poisoning with beta-adrenoceptor blocking agents: recognition and management. Am Heart J. 1979; 98:798-811.
259. Weinstein RS. Recognition and management of poisoning with beta-adrenergic blocking agents. Ann Emerg Med. 1984; 13:1123-31.
260. Anon. Beta-blocker poisoning. Lancet. 1980; 1:803-4.
261. Machin PJ, Hurst DN, Bradshaw RN et al. β-Selective adrenoceptor antagonists. Part 2: 4-ether-linked phenoxypropanolamines. J Med Chem. 1983; 26:1570-6.
262. Broadhurst AD. Comparison of effect on psychomotor performance of single doses of propranolol and acebutolol. Curr Med Res Opin. 1980; 7:33-8.
263. Kayed K, Godtlibsen OB. Central effects of the β-adrenergic blocking agent acebutolol: a quantitative EEG study using normalised slope descriptors. Eur J Clin Pharmacol. 1977; 12:327-31.
264. Kayed K, Godtlibsen OB. Effects of the β-adrenoceptor antagonists acebutolol and metoprolol on sleep pattern in normal subjects. Eur J Clin Pharmacol. 1977; 12:323-6.
265. Lewis MJ, Jones DM, Dart AM et al. The psychological side effects of acebutolol and atenolol. Br J Clin Pharmacol. 1984; 17:364-6.
266. Lewis BS, Mitha AS, Gotsman MS. Acebutolol in cardiac arrhythmias. S Afr Med J. 1974; 4:821-4.
267. Booth RJ, Bullock JY, Wilson JD. Antinuclear antibodies in patients on acebutolol. Br J Clin Pharmacol. 1980; 9:515-7.
268. Wilson FS (Wyeth Laboratories Inc, Philadelphia, PA): Personal communication; 1987.
269. Anon. Choice of a beta-blocker. Med Lett Drugs Ther. 1986; 28:20-2.
270. Wallin JD, Shah SV. β-Adrenergic blocking agents in the treatment of hypertension: choices based on pharmacological properties and patient characteristics. Arch Intern Med. 1987; 147:654-9.
271. McDevitt DG. β-Adrenoceptor blocking drugs and partial agonist activity: is it clinically relevant? Drugs. 1983; 25:331-8.
272. McDevitt DG. Clinical significance of cardioselectivity: state-of-the-art. Drugs. 1983; 25(Suppl 2):219-26.
273. Frishman WH. β-Adrenoceptor antagonists: new drugs and new indications. N Engl J Med. 1981; 305:500-6.
274. Thadani U, Davidson C, Chir B et al. Comparison of the immediate effects of five β-adrenoceptor-blocking drugs with different ancillary properties in angina pectoris. N Engl J Med. 1979; 300:750-5.
275. Lewis RV, McDevitt DG. Adverse reactions and interactions with β-adrenoceptor blocking drugs. Med Toxicol. 1986; 1:343-61.
276. Bradberry JC. Discontinuing β blockers. Clin Pharm. 1984; 3:457,460.
277. Reviewers’ comments (personal observations); 1987.
278. Frishman WH. Clinical differences between beta-adrenergic blocking agents: implications for therapeutic substitution. Am Heart J. 1987; 113:1190-8.
279. Abengowe CU, Rehan N. Acebutolol in the treatment of hypertension in African patients. Curr Ther Res. 1987; 41:737-45.
280. 1988 Joint National Committee. The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1988; 148:1023-38.
281. Tanner LA, Bosco LA, Zimmerman HJ. Hepatic toxicity after acebutolol therapy. Am Intern Med. 1989; 111:533-4.
282. Webster J. Interactions of NSAIDs with diuretics and β-blockers: mechanisms and clinical implications. Drugs. 1985; 30:32-41.
283. Radack KL, Deck CC, Bloomfield SS. Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen. Ann Intern Med. 1987; 107:628-35.
284. Watkins J, Abbott EC, Hensby CN et al. Attenuation of hypotensive effects of propranolol and thiazide diuretics by indomethacin. Br Med J. 1980; 281:702-5.
285. Mills EH, Whitworth JA, Andrews J et al. Non-steroidal anti-inflammatory drugs and blood pressure. Aust N Z J Med. 1982; 12:478-82.
286. Durao V, Prata MM, Goncalves LMP. Modification of antihypertensive effect of β-adrenoreceptor-blocking agents by inhibition of endogenous prostaglandin synthesis. Lancet. 1977; 2:1005-7.
287. Salvetti A, Arzilli F, Pedrinelli R et al. Interaction between oxprenolol and indomethacin on blood pressure in essential hypertensive patients. Eur J Clin Pharmacol. 1982; 22:197-201.
288. Beta blockers/NSAIDs. In: Tatro DS, Olin BR, eds. Drug interaction facts. St. Louis: JB Lippincott Co; 1989: 154.
289. Boissel JP, Lezorovicz A, Picolet H et al. Efficacy of acebutolol after acute myocardial infarction (the APSI Trial). Am J Cardiol. 1990; 66:24-31C.
290. Boissel JP, Leizorovicz A, Picolet H et al. Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol. Am J Cardiol. 1990; 66:251-60.
291. De Backer G. Multicentre study of the efficacy and tolerance of acebutolol versus atenolol in the long term treatment of mild arterial hypertension. Drugs. 1988; 36(Suppl 2):51-6.
292. Clucas A, Miller N. Effects of acebutolol on the serum lipid profile. Drugs. 1988; 36(Suppl 2):41-50.
293. Reviewers’ comments (personal observations).
294. American College of Cardiology and American Heart Association. ACC/AHA guidelines for the early management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee to Develop Guidelines for the Early Management of Patients with Acute Myocardial Infarction). Circulation. 1990; 82:664-707.
295. Goldman L, Sia STB, Cook EF et al. Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction. N Engl J Med. 1988; 319:152-7.
296. Yusuf S, Peto R, Lewis J et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985; 27:335-71.
297. Pedersen TR for the Norwegian Multicenter Study Group. Six-year follow-up of the Norwegian multicenter study on timolol after acute myocardial infarction. N Engl J Med. 1985; 313:1055-8.
298. Frishman WH, Furberg CD, Friedewald WT. β-Adrenergic blockade for survivors of acute myocardial infarction. N Engl J Med. 1984; 310:830-7.
299. Furberg CD. Secondary prophylaxis after acute myocardial infarction. Am J Cardiol. 1987; 60:28-32A.
300. Australian and Swedish Pindolol Study Group. The effect of pindolol on the two years mortality after complicated myocardial infarction. Eur Heart J. 1983; 4:367-75.
301. Schroder R. Oxprenolol in myocardial infarction survivors: brief review of the European infarction study results in light of other beta-blocker postinfarction trials. Z Kardiol. 1985; 74(Suppl 6):165-72.
302. European Infarction Study Group. European infarction study (E.I.S.): a secondary prevention study with slow release oxprenolol after myocardial infarction: morbidity and mortality. Eur Heart J. 1984; 5:189-202.
303. Taylor SH, Silke B, Ebbutt A et al. A long-term prevention study with oxprenolol in coronary heart disease. N Engl J Med. 1982; 307:1293-1301.
305. Wyeth-Ayerst Laboratories, Radnor, PA: Personal communication.
307. Weber MA, Laragh JH. Hypertension: steps forward and steps backward: the Joint National Committee fifth report. Arch Intern Med. 1993; 153:149-52.
308. Collins R, Peto R, MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: an overview of randomized drug trials in their epidemiological context. Lancet. 1990; 335:827-38.
309. Alderman MH. Which antihypertensive drugs first—and why! JAMA. 1992; 267:2786-7. Editorial.
310. MacMahon S, Peto R, Cutler J et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990; 335:765-74.
311. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991; 265:3255-64.
312. Dahlof B, Lindholm LH, Hansson L et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-hypertension). Lancet. 1991; 338:1281-5.
313. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ. 1992; 304:405-12.
314. National Heart, Lung, and Blood Institute. NHLBI panel reviews safety of calcium channel blockers. Rockville, MD; 1995 Aug 31. Press release.
315. National Heart, Lung, and Blood Institute. New analysis regarding the safety of calcium-channel blockers: a statement for health professionals from the National Heart, Lung, and Blood Institute. Rockville, MD; 1995 Sep 1.
316. Psaty BM, Heckbert SR, Koepsell TD et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995; 274:620-5.
317. Yusuf S. Calcium antagonists in coronary artery disease and hypertension: time for reevaluation? Circulation. 1995; 92:1079-82. Editorial.
318. Roche. Posicor (mibefradil hydrochloride) tablets prescribing information. Nutley, NJ; 1997 Dec.
319. Ellison RH. Dear doctor letter regarding appropriate use of Posicor. Nutley, NJ: Roche Laboratories; 1997 Dec.
320. Sidmak Laboratories. Verapamil hydrochloride tablets prescribing information. East Hanover, NJ; 1996 Apr.
321. National Heart, Lung, and Blood Institute National High Blood Pressure Education Program. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Bethesda, MD: National Institutes of Health; 1997 Nov. (NIH publication No. 98-4080.)
322. Kaplan NM. Choice of initial therapy for hypertension. JAMA. 1996; 275:1577-80.
323. Psaty BM, Smith NL, Siscovich DS et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA. 1997; 277:739-45.
324. Whelton PK, Appel LJ, Espeland MA et al. for the TONE Collaborative Research Group. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). JAMA. 1998; 279:839-46.
326. Genuth P. United Kingdom prospective diabetes study results are in. J Fam Pract. 1998; 47:(Suppl 5):S27.
328. Watkins PJ. UKPDS: a message of hope and a need for change. Diabet Med. 1998; 15:895-6.
329. Bretzel RG, Voit K, Schatz H et al. The United Kingdom Prospective Diabetes Study (UKPDS): implications for the pharmacotherapy of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 1998; 106:369-72.
330. Tatti P, Pahor M, Byington RP et al. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998; 21:597-603.
331. American Diabetes Association. The United Kingdom Prospective Diabetes Study (UKPDS) for type 2 diabetes: what you need to know about the results of a long-term study. Washington, DC; 1998 Sep 15 from American Diabetes Association web site.
332. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998; 317:713-20.
333. Davis TME. United Kingdom Prospective Diabetes Study: the end of the beginning? Med J Aust. 1998; 169:511-2.
335. Anon. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Part II. Management of heart failure: apporaches to the prevention of heart failure. Am J Cardiol. 1999; 83:9A-38A.
336. Lim PO, MacDonald TM. Antianginal and β-adrenergic blocking drugs. In: Dukes MNG, ed. Meyler’s side effects of drugs. 13th ed. New York: Elsevier/North Holland Inc; 1996:488-535.
337. Gress TW, Nieto FJ, Shahar E et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med. 2000; 342:905-12.
338. Sowers JR, Bakris GL. Antihypertensive therapy and the risk of type 2 diabetes mellitus. N Engl J Med. 2000; 342:969-70.
339. Izzo JL, Levy D, Black HR. Importance of systolic blood pressure in older Americans. Hypertension. 2000; 35:1021-4.
340. Frohlich ED. Recognition of systolic hypertension for hypertension. Hypertension. 2000; 35:1019-20.
341. Bakris GL, Williams M, Dworkin L et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000; 36:646-61.
342. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998; 351:1755-62.
345. Fuster V, Ryden LE, Asinger RW et al. ACC/AHA/ESC guidelines for the management of atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation). J Am Coll Cardiol. 2001; 38:1266i-lxx.
347. Ryan TJ, Antman EM, Brooks NH et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: 1999 update: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Managment of Acute Myocardial Infarction). From ACC web site.
348. ACC/AHA guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for the Management of Chronic Stable Angina). 2002. From ACC web site. Accessed 2003 Feb 13.
349. Williams CL, Hayman LL, Daniels SR et al. Cardiovascular health in childhood: a statement for health professional from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2002; 106:143-60.
350. Braunwald E, Antman EM, Beasley JW et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). 2002. From ACC web site. Accessed Sep. 10, 2002.
352. Appel LJ. The verdict from ALLHAT—thiazide diuretics are the preferred initial therapy for hypertension. JAMA. 2002; 288:3039-60.
353. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288:2981-97.
355. Douglas JG, Bakris GL, Epstein M et al. Management of high blood pressure in African Americans: Consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003; 163:525-41.
357. The Guidelines Subcommitee of the WHO/ISH Mild Hypertension Liaison Committee. 1999 guidelines for the management of hypertension. J Hypertension. 1999; 17:392-403.
359. Wright JT, Dunn JK, Cutler JA et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005; 293:1595-607.
360. Neaton JD, Kuller LH. Diuretics are color blind. JAMA. 2005; 293:1663-6.
361. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE). Lancet. 2002;359:995-1003.
500. National Heart, Lung, and Blood Institute National High Blood Pressure Education Program. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). Bethesda, MD: National Institutes of Health; 2004 Aug. (NIH publication No. 04-5230.)
501. James PA, Oparil S, Carter BL et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; 311:507-20.
502. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013; 31:1281-357.
503. Go AS, Bauman MA, Coleman King SM et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. Hypertension. 2014; 63:878-85.
504. Weber MA, Schiffrin EL, White WB et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014; 16:14-26.
515. Thomas G, Shishehbor M, Brill D et al. New hypertension guidelines: one size fits most?. Cleve Clin J Med. 2014; 81:178-88.
523. Fihn SD, Gardin JM, Abrams J et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012; 126:e354-471.
524. WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013; 128:e240-327.
527. O'Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 127:e362-425.
800. Yancy CW, Jessup M, Bozkurt B et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016; :.
More about acebutolol
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- 2 Reviews – Add your own review/rating
- Drug class: cardioselective beta blockers
Other brands: Sectral